These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 22770657)

  • 1. Synthetic opioids and arrhythmia risk: a new paradigm?
    Schuller JL; Krantz MJ
    Expert Opin Pharmacother; 2012 Sep; 13(13):1825-7. PubMed ID: 22770657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. QTc interval prolongation by d-propoxyphene: what about other analgesics?
    Raffa RB; Burmeister JJ; Yuvasheva E; Pergolizzi JV
    Expert Opin Pharmacother; 2012 Jul; 13(10):1397-409. PubMed ID: 22568597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioids, QTc prolongation, and torsades.
    Kurt TL
    J Clin Pharmacol; 2012 Oct; 52(10):1614. PubMed ID: 22021567
    [No Abstract]   [Full Text] [Related]  

  • 4. Propoxyphene and pain management in the elderly.
    Mort JR; Schroeder SD
    S D Med; 2009 Nov; 62(11):433-5. PubMed ID: 20128173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Food and Drug Administration recommends against the continued use of propoxyphene.
    Food And Drug Administration Public Health Service U S Department Of Health And Human Services
    J Pain Palliat Care Pharmacother; 2011; 25(1):80-2. PubMed ID: 21426228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propoxyphene (dextropropoxyphene): a critical review of a weak opioid analgesic that should remain in antiquity.
    Barkin RL; Barkin SJ; Barkin DS
    Am J Ther; 2006; 13(6):534-42. PubMed ID: 17122535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexpropoxyphene and cardiac disorders: new data.
    Prescrire Int; 2011 Feb; 20(113):45. PubMed ID: 21491671
    [No Abstract]   [Full Text] [Related]  

  • 8. Close vote by FDA advisers favors propoxyphene withdrawal.
    Traynor K
    Am J Health Syst Pharm; 2009 Mar; 66(6):518-20. PubMed ID: 19265176
    [No Abstract]   [Full Text] [Related]  

  • 9. Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene.
    Shorr RI; Griffin MR; Daugherty JR; Ray WA
    J Gerontol; 1992 Jul; 47(4):M111-5. PubMed ID: 1624693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fatal poisonings involving propoxyphene before and after voluntary withdrawal from the United States' market: An analysis from the state of Florida.
    Delcher C; Chen G; Wang Y; Slavova S; Goldberger BA
    Forensic Sci Int; 2017 Nov; 280():228-232. PubMed ID: 29080523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
    Pearson EC; Woosley RL
    Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analgesics and warfarin. A case that brings up questions and cautions.
    Justice JL; Kline SS
    Postgrad Med; 1988 Apr; 83(5):217-8, 220. PubMed ID: 3357860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk: A Pilot Study.
    Strauss DG; Vicente J; Johannesen L; Blinova K; Mason JW; Weeke P; Behr ER; Roden DM; Woosley R; Kosova G; Rosenberg MA; Newton-Cheh C
    Circulation; 2017 Apr; 135(14):1300-1310. PubMed ID: 28213480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propoxyphene use and risk for hip fractures in older adults.
    Kamal-Bahl SJ; Stuart BC; Beers MH
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):219-26. PubMed ID: 17062322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions.
    Smithburger PL; Seybert AL; Armahizer MJ; Kane-Gill SL
    Expert Opin Drug Saf; 2010 Sep; 9(5):699-712. PubMed ID: 20377471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of propoxyphene withdrawal on opioid use in veterans.
    Hayes CJ; Hudson TJ; Phillips MM; Bursac Z; Williams JS; Austin MA; Edlund MJ; Martin BC
    Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1180-8. PubMed ID: 26248742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propoxyphene and the risk of out-of-hospital death.
    Ray WA; Murray KT; Kawai V; Graham DJ; Cooper WO; Hall K; Stein CM
    Pharmacoepidemiol Drug Saf; 2013 Apr; 22(4):403-12. PubMed ID: 23408551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why pick on propoxyphene? The evidence demands it.
    Hutchison LC
    J Ark Med Soc; 2010 Aug; 107(2):36-7. PubMed ID: 20806582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propoxyphene dependence and withdrawal.
    Strode SW
    Am Fam Physician; 1985 Sep; 32(3):105-8. PubMed ID: 4036770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dextropropoxyphene dependence: a cautionary note.
    Edwin T; Nammalvar N; Ramanujam V
    J Assoc Physicians India; 2001 May; 49():571-3. PubMed ID: 11361277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.